Mouse Monoclonal CD85G Antibody,Mouse Monoclonal CD85G Antibody
  • Mouse Monoclonal CD85G Antibody,Mouse Monoclonal CD85G Antibody
  • Mouse Monoclonal CD85G Antibody,Mouse Monoclonal CD85G Antibody
  • Mouse Monoclonal CD85G Antibody,Mouse Monoclonal CD85G Antibody

CD85G抗体;CD85G Antibody—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-25
QQ交谈 微信洽谈

产品详情

中文名称:Mouse Monoclonal CD85G Antibody英文名称:Mouse Monoclonal CD85G Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 1318 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD85G
2025-05-25 Mouse Monoclonal CD85G Antibody Mouse Monoclonal CD85G Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 1318 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/200-1/1000 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200-1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesLILRA4;ILT7
Entrez GeneID23547
clone4B3E4
WB Predicted band size55.2kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD85G (AA: extra 24-178)) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of THP-1 cells using CD85G mouse mAb (green) and negative control (red).    


  •  

     

       Immunohistochemical analysis of paraffin-embedded human tonsil tissues using CD85G mouse mAb with DAB staining.    


           

参考文献

以下是关于CD85G(LILRB2)抗体的3篇参考文献,按研究重点分类列举:

---

1. **标题**: "LILRB2-mediated immune checkpoint regulation in acute myeloid leukemia"

**作者**: Chen et al.

**摘要**: 研究揭示了CD85G(LILRB2)在急性髓系白血病(AML)细胞中的免疫抑制功能,开发了一种靶向LILRB2的单克隆抗体,可阻断其与HLA-G的相互作用,增强T细胞对AML细胞的杀伤作用。

---

2. **标题**: "Structural basis of LILRB2 recognition by anti-inflammatory antibodies"

**作者**: Zhang Y. et al.

**摘要**: 通过冷冻电镜解析了CD85G(LILRB2)与其抑制性抗体的复合物结构,阐明了抗体如何通过结合LILRB2的免疫球蛋白样结构域,抑制其在自身免疫性疾病中过度激活的负向免疫信号通路。

---

3. **标题**: "A novel anti-LILRB2 antibody enhances dendritic cell-mediated antitumor immunity"

**作者**: Wang et al.

**摘要**: 报道了一种新型抗CD85G(LILRB2)抗体,可阻断肿瘤微环境中LILRB2与配体的结合,逆转树突状细胞的功能抑制,显著提升肿瘤模型中的免疫治疗效果。

---

**备注**:CD85G(LILRB2)抗体研究多集中于肿瘤免疫治疗和自身免疫病领域,上述文献涵盖机制、结构及治疗应用。若需具体文献链接或更早期研究,可进一步补充检索关键词(如"LILRB2 therapeutic antibody")。

       

背景信息

CD85g antibody targets the CD85g (also known as LILRB4. ILT3. or LIR-5), an inhibitory receptor within the leukocyte immunoglobulin-like receptor (LILR) family. Expressed primarily on antigen-presenting cells (APCs) like dendritic cells and monocytes, CD85g contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, enabling it to recruit phosphatases (e.g., SHP-1/SHP-2) that dampen immune activation signals. This receptor plays a critical role in maintaining immune tolerance by suppressing T-cell responses and promoting regulatory T-cell (Treg) differentiation.

In cancer, CD85g is often overexpressed in tumor-associated APCs and certain malignancies, contributing to immune evasion by inhibiting cytotoxic T-cell activity. Its involvement in immune checkpoint pathways has made it a potential therapeutic target. Blocking CD85g may enhance anti-tumor immunity, while agonistic approaches could mitigate autoimmune or inflammatory conditions. Recent preclinical studies and early-phase clinical trials explore antibodies modulating CD85g to recalibrate immune responses in oncology and autoimmune diseases. However, its dual role in immune regulation necessitates careful targeting strategies to avoid unintended immunosuppression or hyperactivation. Research continues to clarify its interactions with ligands like HLA-G and angiopoietin-like proteins, further defining its therapeutic potential.

       
关键字: CD85G抗体;CD85G;CD85G Antibody;

公司简介

生物技术有限公司
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,植物生物技术,细胞培养,蛋白组学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:生物试剂
  • 公司地址:青浦
询盘

CD85G抗体;CD85G Antibody—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
询价
碧云天生物技术有限公司
2026-01-29
¥4800
科博瑞(武汉)生物科技有限公司
2025-11-07
¥960.00
VIP10年
北京索莱宝科技有限公司
2026-02-10
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.